Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
JakaviⓇ - JAK1/2 inhibitor
NCT03491215 REACH4 (CINC424F12201)
Indication
Acute graft versus host disease
Phase 2
Phase
Patients
45
Primary
Measurement of PK parameters
Outcome
Measures
Overall Response Rate (ORR)
Arms
Ruxolitinib
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Intervention
Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic
hematopoietic stem cell transplantation
Target
Patients
Readout
2023
Milestone(s)
Publication
TBD
70 Investor Relations | Q3 2023 Results
JakaviⓇ- JAK1/2 inhibitor
References
Abbreviations
Other
Indication
Phase
NCT03774082 REACH5 (CINC424G12201)
Chronic graft versus host disease
Phase 2
Patients
45
Primary
Overall Response Rate (ORR)
Outcome
Measures
Arms
Intervention
Target
Patients
Ruxolitinib 5mg tablets / pediatric formulation
Pediatric subjects with moderate and severe chronic Graft vs. Host disease
after allogeneic stem cell transplantation
Readout
Milestone(s)
Publication
2023
TBD
NOVARTIS | Reimagining MedicineView entire presentation